Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
505.50    0.50 (0.10%)
Bid:
505.00
Ask:
506.00
Spread: 1.00 (0.198%)
Market Cap: £2.24b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Trading Statement

21 Jul 2016 07:00

21 July 2016 – Tate & Lyle PLC

TRADING STATEMENT

This Trading Statement covers the period from 1 April 2016 to 30 June 2016, which is the first quarter of the financial year.

The Group made a strong start to the year with profit ahead of the comparative period in constant currency. The encouraging start to the year supports our confidence that we will continue to make progress, at constant currency, in the full year.

Speciality Food Ingredients performed solidly with profit for the division overall ahead of the comparative period. Excluding SPLENDA® Sucralose, profit was slightly ahead of the comparative period reflecting good margin improvement. Volume was slightly lower than the comparative period with good growth in Europe, Middle East and Africa, which benefited from the acquisition of the Slovakia facility, and stabilisation in Latin America, more than offset by softer demand in North America, Asia Pacific and Food Systems.

Profit for SPLENDA® Sucralose was significantly higher than the comparative period benefiting from strong volume growth from the sell-down of inventory carried into the financial year following the consolidation of the sucralose manufacturing footprint.

Bulk Ingredients performed strongly with profit well ahead of the comparative period due to solid demand at the start of the US summer beverage season, robust US bulk sweetener margins, and strong manufacturing performance. In Commodities, performance was broadly in line.

The Group generates less than 2% of its revenues in the United Kingdom, with most revenues being US dollar based. Sterling has weakened significantly in recent weeks and, if current exchange rates were to prevail for the remainder of the financial year, our reported earnings would increase strongly1 due to US dollar and other currency movements.

FINANCIAL POSITION AND BALANCE SHEET

Net debt was lower than the position at 31 March 2016 including the currency translation effects of a weaker sterling and the Group’s largely US Dollar denominated debt.

1 With regard to foreign currency, the Group’s results are most sensitive to changes in the US dollar. For the year ended 31 March 2016, it is estimated that a 1 cent change in the sterling:US dollar exchange rate led to a £1.3 million change in adjusted profit before tax. Given the weakening of sterling against most other currencies, changes in the rates of exchange of other currencies is also expected to increase adjusted profit before tax.

END

A conference call will be held today at 07.30am BST, hosted by Javed Ahmed, Chief Executive and Nick Hampton, Chief Financial Officer. Participants are requested to dial in at least 10 minutes before the commencement of the call. Dial in details are as follows:

Standard International Access: +44 (0) 20 3003 2666

Password: Tate & Lyle

A replay of this call will be available after the end of the live call for 14 days until 4 August 2016.

UK replay number: +44 (0) 20 8196 1998

Replay access PIN: 5419118

For more information contact Tate & Lyle PLC:

Christopher Marsh, Group VP, Investor and Media Relations

Tel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7796 192 688

Andrew Lorenz (FTI Consulting), Media Relations

Tel: +44 (0) 203 727 1323 or Mobile: +44 (0) 7775 641 807

About Tate & Lyle:

Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, with operations at more than 25 facilities worldwide.

Tate & Lyle operates through two global divisions, Speciality Food Ingredients and Bulk Ingredients, supported by our Innovation and Commercial Development and Global Operations groups. The Group's strategy is to become a leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving Bulk Ingredients for sustained cash generation to fuel this growth.

Speciality Food Ingredients consists of three platforms: Texturants, which includes speciality starches and stabilisers; Sweeteners, which comprises nutritive sweeteners and our range of no-calorie sweeteners including SPLENDA® Sucralose; and our Health and Wellness portfolio which includes speciality fibres and our salt-reduction offering. Additionally, our Food Systems business provides a wide variety of blended ingredient solutions.

Tate & Lyle Bulk Ingredients includes bulk sweeteners, industrial starches and fermentation products (primarily acidulants). Corn co-products from both divisions are primarily sold as animal feed.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2016, Tate & Lyle sales totalled £2.4 billion. For more information, please visit http://www.tateandlyle.com.

SPLENDA® is a trademark of Heartland Consumer Products LLC.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160720006245/en/

Copyright Business Wire 2016

Date   Source Headline
13th Jun 20253:00 pmRNSHolding(s) in Company
11th Jun 20254:30 pmRNSDirector/PDMR Shareholding
5th Jun 20252:30 pmRNSAnnual Financial Report and Notice of Meeting 2025
5th Jun 20252:00 pmRNSDirector/PDMR Shareholding
2nd Jun 202512:30 pmRNSTotal Voting Rights
28th May 202512:00 pmRNSDirector/PDMR Shareholding
27th May 202512:00 pmRNSDirector/PDMR Shareholding
23rd May 202510:00 amRNSDirector/PDMR Shareholding
22nd May 20257:00 amRNSFinal Results
14th May 20259:00 amRNSHolding(s) in Company
1st May 20253:00 pmRNSHolding(s) in Company
29th Apr 20253:30 pmRNSHolding(s) in Company
28th Apr 20255:15 pmRNSHolding(s) in Company
24th Apr 202512:00 pmRNSHolding(s) in Company
15th Apr 20257:00 amRNSIntegration update and pre-close statement
27th Mar 20257:00 amRNSDirectorate Change
14th Mar 202510:05 amRNSDirectorate declaration
11th Mar 20253:00 pmRNSHolding(s) in Company
5th Mar 202511:30 amRNSDirector/PDMR Shareholding
28th Feb 20254:30 pmRNSHolding(s) in Company
28th Feb 202510:15 amRNSDirector/PDMR Shareholding
27th Feb 20257:00 amRNSAdditional Listing
20th Feb 20251:42 pmRNSDirector/PDMR Shareholding
13th Feb 20257:00 amRNSTrading Statement
4th Feb 20257:05 amRNSDirector Declaration
3rd Feb 20253:30 pmRNSTotal Voting Rights
23rd Jan 20255:30 pmRNSIssue of Debt
9th Jan 20255:54 pmRNSCompletion of Share Buyback Programme
9th Jan 20255:45 pmRNSTransaction in Own Shares
8th Jan 20255:17 pmRNSTransaction in Own Shares
8th Jan 20252:02 pmRNSDirector/PDMR Shareholding
7th Jan 20255:31 pmRNSTransaction in Own Shares
6th Jan 20256:10 pmRNSTransaction in Own Shares
6th Jan 20252:00 pmRNSDirectorate Change
3rd Jan 20255:28 pmRNSTransaction in Own Shares
2nd Jan 20255:20 pmRNSTransaction in Own Shares
2nd Jan 20252:10 pmRNSBlock listing Interim Review
2nd Jan 20252:00 pmRNSTotal Voting Rights
30th Dec 20245:36 pmRNSTransaction in Own Shares
27th Dec 20245:15 pmRNSTransaction in Own Shares
23rd Dec 20245:26 pmRNSTransaction in Own Shares
20th Dec 20245:31 pmRNSTransaction in Own Shares
19th Dec 20245:24 pmRNSTransaction in Own Shares
18th Dec 20245:37 pmRNSTransaction in Own Shares
17th Dec 20245:20 pmRNSTransaction in Own Shares
16th Dec 20245:37 pmRNSTransaction in Own Shares
13th Dec 20245:25 pmRNSTransaction in Own Shares
12th Dec 20245:34 pmRNSTransaction in Own Shares
12th Dec 20245:30 pmRNSDirector/PDMR Shareholding
11th Dec 20245:28 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.